Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSCTC-0010 is an investigational cell therapy product consisting of ex-vivo cultured and expanded mesenchymal stem cells derived from Wharton’s Jelly of the human umbilical cord. It is being developed primarily for the treatment of acute graft-versus-host disease (aGVHD), particularly in patients who are high risk or steroid refractory following allogeneic hematopoietic stem cell transplantation. The mechanism of action involves cell replacement and immunomodulation, leveraging the anti-inflammatory and tissue-repair properties of umbilical cord-derived mesenchymal stromal cells. Early-phase clinical studies have demonstrated that MSCTC-0010 infusions are safe and well-tolerated, with promising clinical responses observed in aGVHD patients[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MSCTC-0010.